Institution identification

Institution ID

3331464

Institution full name and acronym

Novartis Pharmaceuticals

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A 36 month observational study to describe the long-term efficacy and safety of ranibizumab 0.5 mg treatment in patients with visual impairment due to choroidalneovascularization (CNV) secondary to pathologic myopia (PM)
A Cohort Study to Assess Various Safety Outcomes of Interest in Users of Aliskiren Using Claims Data
A drug utilisation study in patients treated with EXELON®/PROMETAX® (rivastigmine) transdermal patch
A European observational registry collecting efficacy and safety data in newly diagnosed pediatric Philadelphia-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients treated with chemotherapy + imatinib ± hematopoietic stem cell treatment (±HSCT)
A multi-database cohort study to assess the incidence rates of colorectal hyperplasia among hypertensive patients
A Non Interventional Long term safety Study of Ruxolitinib in Myelofibrosis (JAKAVI)
A non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries
A phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor® (everolimus RAD001) in combination with exemestane, after progression following therapy with a non-steroidal aromatase inhibitor (BOUDICA)
A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec
A PROSPECTIVE NON-INTERVENTIONAL SAFETY STUDY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING NILOTINIB IN DAILY PRACTICE ACCORDING TO UPDATED GUIDELINES
A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy (SMA) - (RESTORE)
Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM) (Adakveo (crizanlizumab) PRIM)
Alpelisib (Piqray®) Post-Authorization Safety Study (PASS): a non-interventional study of alpelisib in combination with fulvestrant in postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), locally advanced or metastatic breast cancer with a phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutation, in the real-world setting
An international disease registry collecting data on manifestations, interventions and outcomes in patients with tuberous sclerosis complex - TOSCA
An International, Non-Interventional, Post-Authorization Long-Term Safety Study of Lutathera®, in Patients with Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours (SALUS Study)
An observational, multicenter study to evaluate the safety and tolerability of deferasirox in the treatment of pediatric patients with non-transfusion-dependent iron overload (NESO)
An Open-Label, Multi-Centre, Non-Interventional, Post-Marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Votrient Administered in Korean Patients According to the Prescribing Information (115578)
Analysis of pregnancy pharmacovigilance data in spontaneous reports, and literature, (Individual Case Safety Reports originating from published case series, non-interventional studies and patient support programmes); demonstration study 2.5.1 of the ConcePTION project
Angioedema among patients with hypertension treated with aliskiren or other anti-hypertensive medications in the US – a cohort Study and a nested case-control analysis using health claims data
Assessing the Incidence of Ischemic Colitis in Treated Adult Hypertensive Patients in the United States – a Descriptive, Retrospective Cohort Study with Secondary Use of Data from a US Health Claims Database (NA)
Assessing the profile of CHF patients with redUced ejection fraction being managed in the pRimary care sectOr across GeRmany as well as the phArmacologic treatment these HF patients receive (AURORA-HF)
Assessment of Real LIfe cAre – Describing EuropeaN Heart FailurE Management (ARIADNE)
Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for HR+ Women (BRAWO)
Building a pregnancy pharmacovigilance model for the future: Can pregnancy data collected by ConcePTION partners be analysed using common standards developed by the ConcePTION project?
Demonstration study 2.5.5 of the ConcePTION project; Validation of primary source pregnancy exposure and outcomes (pharmacovigilance data)
Drug Use Investigation for Arzerra Chronic Lymphocytic Leukemia (CLL) (116789)
Evaluation of pregnancy and infant outcomes in Kesimpta patients using PRegnancy outcomes Intensive Monitoring (PRIM) data - The Kesimpta-PRIM study. (The Kesimpta PRIM study.)
Evaluation of pregnancy and infant outcomes in Mayzent patients using PRegnancy outcomes Intensive Monitoring (PRIM) data – The Mayzent-PRIM study
Incidence of colorectal hyperplasia and gastrointestinal cancer in treated adult hypertensive patients in the United States – a cohort study based on secondary use of health data
INJECT: Investigation of JETREA® in patients with confirmed vitreo-macular traction
Kesimpta (ofatumumab) pregnancy and infant safety study using real world data
Kesimpta long-term retrospective safety study utilizing real- world data from existing multiple sclerosis registries and databases from multiple countries
Monitoring of pregnancy outcomes in women treated with inclisiran: a non-interventional study
Multinational database cohort study to assess RMP specified safety outcomes in association with indacaterol/glycopyrronium bromide in Europe
Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe (NVA237 PASS)
Multinational, multi-database drug utilization study of inhaled NVA237 in Europe (NVA237 DUS)
Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®)
Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure
Observational prospective study in post-menopausal women with advanced HR+/HER2- breast cancer treated with a combination of Afinitor® + exemestane to describe the management of two Adverse Events, non-infectious lung disease and stomatitis (TANGO)
Outpatient care with long-acting bronchodilators: COPD Register in Germany (DACCORD)
Panobinostat Post Authorization Safety Study, a non-interventional study of panobinostat in combination with bortezomib and dexamethasone in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated with Kesimpta (ofatumumab) using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry (Kesimpta Pregnancy Registry)
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated with Mayzent (siponimod): An OTIS Observational Pregnancy Surveillance Study
Post-authorization safety study of iptacopan in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) using data from the non-interventional IPIG PNH Registry
PRINCIPAL: A prospective observational study of real world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma receiving pazopanib (115232)
Program to evaluate the Tasigna (nilotinib) educational materials: survey to patients and physicians in five EU countries
PROSPECT: Observational, descriptive study of PRior and concomitant psoriasis treatments in patients receiving Secukinumab in the routine treatment of moderate to severe plaque-type psoriasiss
Registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel
Reporting and Analysis Plan - ECHO Analyses From Randomized Controlled Trials of Dabrafenib to Evaluate the Potential for Cardiac Valve Abnormalities (201709)
Reporting and Analysis Plan - Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials (201710)
Retrospective analysis of imaging and clinical features from patients treated with brolucizumab in post-marketing setting with reports of intraocular inflammation and/or retinal vascular occlusion
Retrospective analysis of safety in elderly metastatic or unresectable BRAF V600 melanoma patients treated with Tafinlar (dabrafenib) plus Mekinist (trametinib) and correlation with clinical features and non-elderly patients
Survey among healthcare professionals (neurologists treating patients with MS along with MS specialist nurses) and patients in selected European countries plus Canada to evaluate the knowledge required for the safe use of Mayzent (siponimod)
Survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycemia when using alpelisib
Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (Gilenya Pregnancy Registry)
Usage Patterns of Selected Systemic NSAIDs (Including Diclofenac): A Retrospective Cohort Study
Use of inhaled long acting beta2 adrenoceptor agonists and the risk for Acute Myocardial Infarction (AMI). A methodological comparison across data sources and epidemiological design
WEUSKOP7135: A prospective, observational cohort study nested within the HCV TARGET study to evaluate real-world use (201110)
WEUSKOP7136: A global, prospective cohort study to evaluate the real-world use of eltrombopag in adult patients with chronic Hepatitis C Virus infection who are unable to initiate or maintain optimal interferon-based therapy due to thrombocytopenia (201111)